Interaction Checker

Upadacitinib interactions

Upadacitinib (Rinvoq), an immunosuppressant has 99 documented interactions across the FDA labels and fact sheets we index: 70 major, 27 moderate, 2 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Major interactions (70)

  • AbataceptimmunosuppressantMajor

    Additionally, concomitant use of ORENCIA with other biologic RA/PsA therapy or JAK inhibitors is not recommended. (Abatacept label, Warnings and precautions)

  • AdalimumabimmunosuppressantMajor

    …safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor [see Warnings and Precautions ( 5.2 )] . (Upadacitinib label, Boxed warning)

  • AmiodaroneantiarrhythmicMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • AprepitantCYP3A4 inhibitorMajor

    Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (Upadacitinib label, Drug interactions)

  • ArmodafinilCNS stimulantMajor

    Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (Upadacitinib label, Drug interactions)

  • BeclomethasonecorticosteroidMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • BetamethasonecorticosteroidMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • BosentanCYP3A4 inducerMajor

    Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (Upadacitinib label, Drug interactions)

  • BudesonidecorticosteroidMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • Budesonide and formoterolcorticosteroidMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • CaptoprilACE inhibitorMajor

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (Captopril label, Warnings)

  • CarbamazepineanticonvulsantMajor

    Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (Upadacitinib label, Drug interactions)

  • CenobamateanticonvulsantMajor

    Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (Upadacitinib label, Drug interactions)

  • CimetidineH2 blockerMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • Clarithromycinmacrolide antibioticMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • ClobazambenzodiazepineMajor

    Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (Upadacitinib label, Drug interactions)

  • ClobetasolcorticosteroidMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • CyclosporineimmunosuppressantMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • Deferasiroxiron supplementMajor

    Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (Upadacitinib label, Drug interactions)

  • DesonidecorticosteroidMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • DexamethasonecorticosteroidMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • Diltiazemcalcium channel blockerMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • DronedaroneantiarrhythmicMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • Erythromycinmacrolide antibioticMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • EslicarbazepineanticonvulsantMajor

    Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (Upadacitinib label, Drug interactions)

  • EtanerceptimmunosuppressantMajor

    …safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor [see Warnings and Precautions ( 5.2 )] . (Upadacitinib label, Boxed warning)

  • EverolimusimmunosuppressantMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • Fluconazoleazole antifungalMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • FludrocortisonecorticosteroidMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • FluocinonidecorticosteroidMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • FluticasonecorticosteroidMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • Fluticasone and salmeterolcorticosteroidMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • GrapefruitFood and drinkMajor

    Food or drink containing grapefruit should be avoided during treatment with RINVOQ/RINVOQ LQ. (Upadacitinib label, Drug interactions)

  • GriseofulvinantifungalMajor

    Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (Upadacitinib label, Drug interactions)

  • HalobetasolcorticosteroidMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • HydrocortisonecorticosteroidMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • ImatinibCYP3A4 inhibitorMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • InfliximabimmunosuppressantMajor

    …safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor [see Warnings and Precautions ( 5.2 )] . (Upadacitinib label, Boxed warning)

  • IsoniazidantibioticMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • Itraconazoleazole antifungalMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • IvacaftorCYP3A4 inhibitorMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • Ketoconazoleazole antifungalMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • MethotrexateimmunosuppressantMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • MethylprednisolonecorticosteroidMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • Mirabegronbeta-adrenergic agonistMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • ModafinilCNS stimulantMajor

    Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (Upadacitinib label, Drug interactions)

  • MometasonecorticosteroidMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • Nirmatrelvir and ritonavirantiviralMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • OxcarbazepineanticonvulsantMajor

    Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (Upadacitinib label, Drug interactions)

  • PalbociclibCYP3A4 inhibitorMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • PerampanelanticonvulsantMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • PhenobarbitalbarbiturateMajor

    Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (Upadacitinib label, Drug interactions)

  • Phentermine and topiramateCNS stimulantMajor

    Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (Upadacitinib label, Drug interactions)

  • PhenytoinanticonvulsantMajor

    Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (Upadacitinib label, Drug interactions)

  • Posaconazoleazole antifungalMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • PrednisolonecorticosteroidMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • PrednisonecorticosteroidMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • PrimidoneanticonvulsantMajor

    Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (Upadacitinib label, Drug interactions)

  • RanolazineQT-prolonging drugMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • RifampinantibioticMajor

    Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (Upadacitinib label, Drug interactions)

  • RitonavirantiretroviralMajor

    Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (Upadacitinib label, Drug interactions)

  • Suvorexantsedative-hypnoticMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • TacrolimusimmunosuppressantMajor

    …IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (Tacrolimus label, Boxed warning)

  • Ticagrelorantiplatelet agentMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • Tobacco and smokingTobacco and cannabisMajor

    Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions ( 5.3 )] . (Upadacitinib label, Boxed warning)

  • TofacitinibimmunosuppressantMajor

    …randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor [see Warnings… (Upadacitinib label, Boxed warning)

  • TopiramateanticonvulsantMajor

    Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (Upadacitinib label, Drug interactions)

  • TriamcinolonecorticosteroidMajor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadacitinib label, Boxed warning)

  • Verapamilcalcium channel blockerMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

  • Voriconazoleazole antifungalMajor

    For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadacitinib label, Drug interactions)

Moderate interactions (27)

  • Amlodipinedihydropyridine calcium channel blockerModerate

    Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipine label, Drug interactions)

  • AspirinNSAIDModerate

    Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (Upadacitinib label, Warnings and precautions)

  • Aspirin and dipyridamoleantiplatelet agentModerate

    Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (Upadacitinib label, Warnings and precautions)

  • AtorvastatinstatinModerate

    Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. (Upadacitinib label, Warnings and precautions)

  • CelecoxibNSAIDModerate

    Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (Upadacitinib label, Warnings and precautions)

  • DenosumabModerate

    Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (Denosumab label, Warnings and precautions)

  • DiclofenacNSAIDModerate

    Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (Upadacitinib label, Warnings and precautions)

  • EtodolacNSAIDModerate

    Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (Upadacitinib label, Warnings and precautions)

  • Ezetimibe and simvastatinstatinModerate

    Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. (Upadacitinib label, Warnings and precautions)

  • FenofibratefibrateModerate

    Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including fenofibrate, there is a risk that an interaction will lead to deterioration of renal… (Fenofibrate label, Drug interactions)

  • FluvastatinstatinModerate

    Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. (Upadacitinib label, Warnings and precautions)

  • IbuprofenNSAIDModerate

    Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (Upadacitinib label, Warnings and precautions)

  • IndomethacinNSAIDModerate

    Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (Upadacitinib label, Warnings and precautions)

  • KetorolacNSAIDModerate

    Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (Upadacitinib label, Warnings and precautions)

  • LeflunomideimmunosuppressantModerate

    If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (Leflunomide label, Warnings and precautions)

  • LovastatinstatinModerate

    Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. (Upadacitinib label, Warnings and precautions)

  • MeloxicamNSAIDModerate

    Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (Upadacitinib label, Warnings and precautions)

  • MycophenolateimmunosuppressantModerate

    Lymphoma and Other Malignancies Patients receiving immunosuppressants, including MYHIBBIN, are at increased risk of developing lymphomas and other malignancies, particularly of the skin [see Adverse Reactions ( 6.1 )]. (Mycophenolate label, Warnings and precautions)

  • NabumetoneNSAIDModerate

    Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (Upadacitinib label, Warnings and precautions)

  • NaproxenNSAIDModerate

    Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (Upadacitinib label, Warnings and precautions)

  • PitavastatinstatinModerate

    Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. (Upadacitinib label, Warnings and precautions)

  • PravastatinstatinModerate

    Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. (Upadacitinib label, Warnings and precautions)

  • RosuvastatinstatinModerate

    Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. (Upadacitinib label, Warnings and precautions)

  • SimvastatinstatinModerate

    Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. (Upadacitinib label, Warnings and precautions)

  • Sofosbuvir and velpatasvirantiviralModerate

    HBV reactivation has also been reported in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (Sofosbuvir and velpatasvir label, Warnings and precautions)

  • Sumatriptan and naproxentriptanModerate

    Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (Upadacitinib label, Warnings and precautions)

  • TinidazoleantibioticModerate

    Cyclosporine, tacrolimus: Monitor for toxicities of these immunosuppressive drugs ( 7.1 ) (Tinidazole label, Drug interactions)

Minor mentions (2)

  • Methimazoleantithyroid drugMinor

    In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (Methimazole label, Warnings)

  • Propylthiouracilantithyroid drugMinor

    In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (Propylthiouracil label, Warnings)

Check Upadacitinib against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.